Wednesday’s decisive Supreme Court ruling against Wyeth in a landmark pharmaceutical product liability case also may close off a major front in a hard-fought battle by businesses and the Bush administration to insulate national corporations from state tort litigation.
The high court’s decision is the second blow to attempts to protect drug companies from suits after their activities have won Food and Drug Administration approval. In Georgia last week, a Senate committee rejected Gov. Sonny Perdue’s attempt to provide immunity from product-liability suits to Georgia companies whose products have FDA approval.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
